ABSTRACT
In a randomised double-blind study 122 volunteers living in an endemic malarious area in Amazonian Rondônia state were divided into 4 groups to study malaria suppression. . The first group received 500 mg of mefloquine every month, group II 250 mg every two weeks, group III a tablet of Fansidar (500 mg sulphadoxine + 25mg pyrimethamine) a week and group IV placebo. Acute attacks of malaria occurred in one individual in group I, 2 subject in group II, and 6 individuals in groups III and IV. Protection with mefloquine was significant compared with the placebo group. Both treatment regimens with mefloquine were effective suppressants in an area of high prevalence of drug multiresistant Plasmodium falciparum transmission.
Subject(s)
Malaria, Falciparum/prevention & control , Malaria, Vivax/prevention & control , Mefloquine/therapeutic use , Adolescent , Adult , Brazil , Dose-Response Relationship, Drug , Double-Blind Method , Female , Humans , Male , Mefloquine/adverse effects , Middle Aged , Time FactorsABSTRACT
Os autores descrevem um caso de infeccao pelo P. falciparum, que apresentou resistencia "in vivo" a nivel de RIII, para o tratamento com a associacao sulfadoxina + pirimetamina
Subject(s)
Child , Humans , Male , Female , Malaria , Plasmodium falciparum , Pyrimethamine , Sulfadoxine , Brazil , Drug Resistance, MicrobialABSTRACT
Os autores descrevem o emprego de clindamicina em dois esquemas, no tratamento da infeccao malarica pelo P. falciparum. Foram tratados 19 pacientes com dosagem de 20 mg/kg/peso durante tres dias e 17 pacientes por sete dias. O esquema de tratamento em sete dias mostrou ser mais eficaz em tratar e curar os pacientes
